Stocktoria
Tempest Therapeutics, Inc. TPST
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-10-04
Tempest Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$26.6M | -$42.0M | -$29.2M | -$34.6M | -$27.0M |
| Interest expense | — | — | $1.4M | $1.6M | $1.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M | -$28.3M |
| EPS (diluted) | $-6.33 | $-19.50 | $-1.91 | $-3.09 | $-7.47 |
| Operating cash flow | -$26.8M | -$33.0M | -$27.4M | -$31.1M | -$26.0M |
| Free cash flow | -$26.8M | -$33.5M | -$27.5M | -$31.6M | -$26.1M |
| Cash & equivalents | $7.7M | $30.3M | $39.2M | $31.2M | $51.8M |
| Total assets | $16.9M | $41.5M | $51.6M | $46.1M | $73.2M |
| Total liabilities | $10.3M | $22.4M | $24.8M | $28.0M | $37.1M |
| Shareholders' equity | $6.7M | $19.1M | $26.8M | $18.1M | $36.1M |
Source: SEC EDGAR filings · CIK 0001544227 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.